Serum and supernatant levels and membrane expression of CD23
| . | sCD23 (U/mL) . | % CD19+/CD23+ . | % CD19+/CD23− . | % CD19−/CD23+ . |
|---|---|---|---|---|
| BL41 | 0* | 0 | 99.9 | 0 |
| BL41/B95-8 | 285* | 38.9 | 59.1 | 0 |
| PBMC HD (n = 3) | 112 ± 8 | 4.5 ± 0.6 | 1.8 ± 0.4 | 0.6 ± 0.2 |
| CLLCD23+/− | 120 | 31.8 | 57 | 0.9 |
| CLL 1 | 998 | 85.3 | 0.7 | 0.6 |
| CLL 2 | 1670 | 90.4 | 4 | 0.9 |
| CLL 3 | 2119 | 89.5 | 1.8 | 0.4 |
| CLL 4 | 2518 | 72.2 | 6 | 4.9 |
| CLL 5 | 3551 | 91.1 | 5.9 | 0.9 |
| CLL 6 | 4310 | 93.4 | 4.7 | 0.5 |
| . | sCD23 (U/mL) . | % CD19+/CD23+ . | % CD19+/CD23− . | % CD19−/CD23+ . |
|---|---|---|---|---|
| BL41 | 0* | 0 | 99.9 | 0 |
| BL41/B95-8 | 285* | 38.9 | 59.1 | 0 |
| PBMC HD (n = 3) | 112 ± 8 | 4.5 ± 0.6 | 1.8 ± 0.4 | 0.6 ± 0.2 |
| CLLCD23+/− | 120 | 31.8 | 57 | 0.9 |
| CLL 1 | 998 | 85.3 | 0.7 | 0.6 |
| CLL 2 | 1670 | 90.4 | 4 | 0.9 |
| CLL 3 | 2119 | 89.5 | 1.8 | 0.4 |
| CLL 4 | 2518 | 72.2 | 6 | 4.9 |
| CLL 5 | 3551 | 91.1 | 5.9 | 0.9 |
| CLL 6 | 4310 | 93.4 | 4.7 | 0.5 |
The soluble CD23 (sCD23) concentrations were determined by enzyme-linked immunosorbent assay in serum obtained from 3 representative healthy donors (HDs); data represent mean ± SEM. One patient with atypical B-cell chronic lymphocytic leukemia (B-CLL) (CLLCD23+/−) and 6 patients with typical B-CLL (CLL 1-6) enrolled in this study. The percentage of CD19+ and CD23+ cells from total cell populations were determined by using flow cytometry.
PBMC indicates peripheral blood mononuclear cell.
The sCD23 levels of BL41 and of BL41/B95-8 cells were measured in supernatants after a culture period of 48 hours.